SCYNEXIS, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
SCYNEXIS, Inc. (SCYX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2024-11-06
- SCYNEXIS, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-09-30 was 0.00 shares.
- SCYNEXIS, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 0.00 shares.
- SCYNEXIS, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 1.14M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-08 | 0.00 shares 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 1.14M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 1.14M shares 10-Q · filed 2024-08-08 | 1.14M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | ||||
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-13 | 0.00 shares 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 0.00 shares 10-Q · filed 2023-08-14 | 0.00 shares 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 1.14M shares 10-Q · filed 2023-05-10 | ||||
| 2021-09-30 | 1.14M shares 10-Q · filed 2022-11-09 | 0.00 shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-15 | 0.00 shares 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-12 | ||||
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-10 | 2.76M shares 10-Q · filed 2020-11-06 | 0.00 shares 10-Q · filed 2021-11-10 | 1.09M shares 10-Q · filed 2020-11-06 | |
| 2019-09-30 | 1.14M shares 10-Q · filed 2020-11-06 | 11.38M shares 10-Q · filed 2019-11-12 | 0.00 shares 10-Q · filed 2020-11-06 | ||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-12 | 0.00 shares 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |